Zurich-Schlieren, May 30, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 [...]
Zurich-Schlieren, May 12, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., cofounder of the company, as Chief Executive Officer and to nominate him [...]
Long-term venture capital investors holding reduced to 28% of share capital. Private investors acquired shares from venture capitalist investors in secondary block trades. Zurich-Schlieren, April 6, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today reported changes [...]
Symetis launches its IPO on Euronext Paris Symetis develops, produces and markets heart valve replacement solutions for the treatment of severe cardiac valve conditions. The company plans to raise € 55.8 million that could be increased to approximately € 64.1 million in the event of full exercise of [...]
Symetis launches €55M IPO for artificial heart valves The Swiss medtech company Symetis has launched a €55M IPO to accelerate the development of its next-generation heart valve replacement solutions. Symetis develops next-generation heart valve replacements for the treatment of cardiac valve conditions. With its current €55M IPO on [...]
Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions Symetis’ [...]
Vertiflex. Inc. completes $40 million financing round PMA approved Superion® demonstrating early commercial success Carlsbad, CA (March 8, 2017) – Vertiflex, Inc., a leading innovator of advanced, minimally invasive interventions for spinal stenosis, today announced completion of a $40M financing round. New investors, Endeavour Vision and H.I.G. BioHealth [...]
Tianjin, People’s Republic of China, 27 June 2016 – Quid, headquartered in San Francisco, was today awarded as one of the World Economic Forum’s Technology Pioneers, a selection of the world’s most innovative companies. Quid is software that searches, analyzes and visualizes the world’s collective intelligence to help answer [...]
Endeavour Medtech Growth (EMG) Fund final close at EUR 250m (USD 275m) EMG is the largest fund in Europe dedicated to medtech Fund oversubscribed – significantly exceeds EUR 150m target Fund to allocate between EUR 10m and EUR 20m per investment St Peter Port, Guernsey – 22 March 2016 [...]
Lausanne/Ecublens, Switzerland, September 1, 2015 – Symetis SA, a leading Swiss medical technology company, focused on transcatheter aortic valve implantation (TAVI), announced today its intention to float its shares and list on SIX Swiss Exchange in 2015. Proceeds from the initial public offering (IPO) will enable the company to [...]